Therapeutical options provided by new antiepileptic drugs;Options therapeutiques offertes par les nouveaux medicaments antiepileptiques

Revue Neurologique

Volumn 153, Issue 1, 1997, Pages 21-33

  Baulac, M ^a   Arzimanoglou, A ^a   Semah, F ^a   Cavalcanti, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; GABAPENTIN; LAMOTRIGINE; NEW DRUG; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ATAXIA; DIPLOPIA; DROWSINESS; EPILEPSY; HUMAN; RASH; REVIEW; SEIZURE; TREMOR; VERTIGO; WEIGHT GAIN; ADULT; AGED; CHILD; FEMALE; NEWBORN; PREGNANCY;

ADULT; AGED; ANTICONVULSANTS; CHILD; EPILEPSY; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY;

EID: 0030897530     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. AICARDI J., and the coordinating Peer Review Group. (1995). European experience with the use of vigabatrin as first-line monotherapy in infantile spasms. Epilepsia, 36 : S102.
2. AICARDI J., ARZIMANOGLOU A. (1996). Treatment of the childhood epilepsy syndromes. In : S. Shorvon et al. (eds), the treatment of epilepsy, Londres, Blackwell Scientific, pp. 199-214.
3. ANHUT H., ASHMAN P., FEUERSTEIN T.J., SAUERMANN W., SAUNDERS M., SCHMIDT B., and the international study group. (1994). Gabapentin (Neurontin) as add-on therapy in patients with partial seizures : a double-blind, placebo-controlled study. Epilepsia, 35 : 795-801.
4. ARZIMANOGLOU A., GERARDIN V., MOSKOWSKI J., BIDAUT C. (1993). Lamotrigine in patients with childhood onset intractable epilepsy. Epilepsia, 34 : 113.
5. ARZIMANOGLOU A.A., DUMAS C., GHIRARDI L., and the French Neurologists Sabril study group. (1995). Clinical experience with vigabatrin in 401 out patients with non severe partial epilepsy. Epilepsia, 36 (Suppl. 3) : S105.
6. BAKER G., SMITH D., DEWEY M., MORROW J., CRAWFORD P., CHADWICK D. (1991). The development of a seizure severity scale as an outcome measure in epilepsy. Epilepsy Res, 8 : 245-251.
7. BAULAC M. (1992). Simplification des traitements antiépileptiques. Epilepsies, 4 : 125-132.
8. BEDNAREK N., and the French Collaborative Study Group. (1995). Efficay of lamotrigine in pharmacoresistant absences. Epilepsia, 36 : S114.
9. BEGLEY C.E., ANNEGERS J.F., LARSON D.R., REYNOLDS T.F., HAUSER W.A. (1994). Cost of epilepsy in the United States : a model based on incidence and prognosis. Epilepsia, 35 : 1230-1243.
10. BEN-MENACHEM E. (1995a). Topiramate. In : Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs, Fourth Edition. New York : Raven Press, pp. 1063-1070.
11. BEN-MENACHEM E. (1995b). International experience with Tiagabine add-on therapy. Epilepsia, 36 (Suppl. 6) : S14-S21.
12. BETTS T. (1990). Communication of pooled results of 27 open studies of lamotrigine as add-on therapy for up to 12 months in adults with treatment resistant epilepsy. J Neurol, 237 (Suppl. 1) : S52.
13. BINNIE C.D., DEBETS R.M.C., ENGELSMAN M. et al. (1989). Double-blind cross-over trial of Lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res, 4 : 222-229.
14. BITTENCOURT P.R.M. DE., MAZER S., MARCOURAKIS T. et al. (1994). Vigabatrin : clinical evidence supporting rational polytherapy in management of uncontrolled seizures. Epilepsia, 35 : 373-380.
15. BOURGEOIS B.F.D. (1995). Important pharmacokinetic properties of antiepileptic drugs. Epilepsia, 36 (Suppl. 5) : S1-S7.
16. BRODIE M.J. (1992). Lamotrigine. Lancet, 339 : 1397-1400.
17. BRODIE M.J. (1995). Tiagabine pharmacology in profile. Epilepsia, 36 (Suppl. 6) : S7-S9.
18. BRODIE M.J., RICHENS A., YUEN A.W.C. (1995). Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet, 345 (i) : 476-479.
19. BRODIE M.J. (1996). Antiepileptic drugs, clinical trials, and the market place. Lancet, 347 : 777-778.
20. BROGLIN D. (1994). Pharmacologie des médicaments antiépileptiques : Mécanismes d'action. In : Aspects fondamentaux des épilepsies. Documentation médicale Sanofi Winthrop, 185-204.
21. BROWNE T.R., MATTSON R.H., PENRY J.K. et al. (1991). Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures ; an update. Neurology, 41 : 363-364.
22. CANNON D.J., BUTLER W.H., MUNFORD J.P. et al. (1991). Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol, 6 : S17-24.
23. CHADWICK D.W. (1994). Gabapentin. Lancet, 343 (i) : 89-91.
24. CEREGHINO J.J. (1992). Clinical trial design for antiepileptic drugs. Annals of Neurology, 32 : 393-394.
25. CHIRON C., DULAC O., BEAUMONT D. et al. (1991). Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol, 6 : 2S52-2S59.
26. CHIRON C., DUMAS C., DULAC O. et al. (1995). Vigabatrin versus hydrocortisone as first-line monotherapy in infantile spasms due to tuberous sclerosis. Epilepsia, 36 : S265.
27. COMMISSION ON ANTIEPILEPTIC DRUGS OF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY (1989). Guidelines for clinical evaluation of antiepileptic drugs. Epilepsia, 30 : 400-408.
28. COMMISSION ON ANTIEPILEPTIC DRUG OF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY (1994). Guidelines for antiepileptic drug trials in children. Epilepsia, 35 : 94-100.
29. CRAMER J.A., MATTSON R.H., PREVEY M.L. (1989). How often is medication taken as prescribed ? A novel assessment technic. JAMA, 261 : 3273-3277.
30. DAM M., EKBERG R., LÖYNING Y., WALTIMO O., JAKOBSEN K. (1989). A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously intreated epilepsy. Epilepsy Res, 3 : 70-76.
31. DAM M., OSTERGAARD L.H. (1995). Oxcarbazepine. In : Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs, Fourth Edition. New York : Raven Press, pp. 987-985.
32. DODRILL C.B., ARNETT J.L., SOMMERVILLE K.W., SUSSMAN N.M. (1993). Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology, 43 : 2501-2507.
33. DODRILL C.B., ARNETT J.L. et al. (1995). Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia, 36 : 164-173.
34. DULAC O., CHIRON C., LUNA D., CUSMAI R., PAJOT N., BEAUMONT D., MONTDRAGON S. (1991). Vigabatrin in childhood epilepsy. J Child Neurol, 6 (Suppl. 2) : S30-S37.
35. DULAC O., N'GUYEN T. (1993). The Lennox-Gastaut syndrome. Epilepsia, 34 (Suppl. 7) : S7-S17.
36. DUVAL X., CHOSIDOW O., SEMAH F., LIPSKER D., FRANCES C., HERSON S. (1995). Letter to the Lancet : Lamotrigine versus carbamazepine in epilepsy. Lancet, 345 (i) : 1301-1302.
37. ENGEL J. Jr. (1996). Surgery for seizures. N Engl J Med, 334 : 647-652.
38. FELBAMATE STUDY GROUP IN LENNOC-GASTAUT SYNDROME. (1993). Efficacy of felbamate in childhood epileptic enoephalopathy (Lennox-Gastaut Syndrome). N Engl J Med, 328 : 29-33.
39. FERENDELLI J.A. (1995). Relating pharmacology to clinical practice : the pharmacologic basis of rational polypharmacy. Neurology, 45 (Suppl. 2) : S12-S16.
40. FERRIE C.D., ROBINSON R.O., KNOTT C., PANAYIOTOPOULOS C.P. (1995). Lamotrigine as a add-on drug in typical absence seizures. Acta Neurol Scand, 91 : 200-202.
41. GRAM L., KLOSTERSKOV P., DAM M. (1985). Gamma-vinyl GABA : a double-blind, placebo-controlled trial in partial epilepsy. Ann Neurol, 17 : 262-266.
42. GRAM L., DULAC O. (1995). Antiepileptic drug-induced worsening of seizures in adults and children. Epilepsia, 36 (Suppl. 3) : S57.
43. HAUSER W.A. (1992). Seizure disorders : the changes with age. Epilepsia, 33 (Suppl. 4) : S6-S14.
44. HAUSER W.A., HESDORFFER D.C. (1990). Epilepsy : frequency, causes and consequences. New York, Demos Press.
45. HIRSCH E., DUTOYA S., STRUMIA S., MARESCAUX C. (1995). Lamotrigine and generalized epileptic syndromes. Epilepsia, 36 : 112.
46. JACKSON G.D., GRUNEWALD R.A., CONNELLY A. et al. (1994). Quantitative MR relaxometry study effects of vigabatrin in the brains of epilepsy patients. Epilepsy Res, 18 : 127-137.
47. JOHANESSEN S.I. (1995). Laboratory monitoring of antiepileptic drugs. In : Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs, Fourth Edition. New York : Raven Press, pp. 179-187.
48. JUNG M.J., PALFREYMAN M.G. (1995). Vigabatrin, mechanisms of action. In : Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs, Fourth Edition. New York : Raven Press, pp. 903-913.
49. KäLVIÄINEN R., ÄIKIÄ M. et al. (1995). Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Archives of Neurology, 52 : 989-996.
50. KRAMER L.D., PLEDGER G.W. et al. (1993). Prototype antiepileptic drug clinical development plan. Epilepsia, 34 : 1075-1084.
51. LEACH M.J., LEES G., RIDDALL D.R. (1995). Lamotrigine, mechanisms of action. In : Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs, Fourth Edition. New York : Raven Press, pp. 861-869.
52. LEE D.O., SREINGARD R.J., CESENA M. et al. (1996). Behavioral side effects of gabapentin in children. Epilepsia, 37 : 87-90.
53. LEIDERMAN D.B. (1994). Gabapentin as add-on therapy for refractory partial epilepsy : results of five placebo-controlled trials. Epilepsia, 35 (Suppl. 5) : S74-S76.
54. LEPPIK I.O. (1995). Felbamate. Epilepsia, 36 (Suppl. 2) : S66-S72.
55. LINDHOUT D., OMTZIGT J.G.C. (1994). Teratogenic effects of antiepileptic drugs : implications for the management of epilepsy in women of childbearing age. Epilepsia, 35 (Suppl. 4) : S19-S28.
56. LIVINGSTON J.H., BEAUMONT D., ARZIMANOGLOU A., AICARDI J. (1989). Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol, 27 : 109S-112S.
57. LINDHOUT D., OMTZIGT J.G.G. (1994). Teratogenic effects of antiepileptic drugs : implications for the management of epilepsy in women of childbearing age. Epilepsia, 35 (Suppl. 4) : S19-S28.
58. LOISEAU P., HARDENBERG J.P., PESTRE M. (1986). Double-blind placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug resistant epilepsy. Epilepsia, 27 : 115-120.
59. LOISEAU P., YUEN A.W.C., DUCHE B., MENAGER T., ARNE-BES M.C. (1990). A randomized double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment resistant partial seizures. Epilepsy Res, 7 : 136-145.
60. LOISEAU P., DUCHE B. (1995). Stiripentol. In : Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs, Fourth Edition. New York : Raven Press, pp. 1045-1056.
61. LÖSCHER W., SCHMIDT D. (1994). Strategies in antiepileptic drug development : is rational drug design superior to random screening and structural variation ? Epilepsy Res, 17 : 95-134.
62. LUNA D., DULAC O., PAJOT N., BEAUMONT D. (1989). Vigabatrin in the control of childhood epilepsies : a single-blind placebo-controlled study. Epilepsia, 30 : 430-437.
63. Mc GUIRE A.M., DUNCAN J.S., TRIMBLE M.R. (1992). Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia, 33 : 128-134.
64. MARSON A.G., KADIR Z.A., CHADWICK D.W. (1996). New antiepileptic drugs : a systematic review of their efficacy and tolerability. BMJ, 313 : 1169-74.
65. MATSUO F., BERGEN D., FAUGHT E., MESSENHEIMER J.A., DREN A.T., RUDD G.D., LINEBERRY G.D. (1993). Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology, 43 : 2284-2291.
66. MATTSON R.H., CRAMER J.A., COLLINS J.F. and the department of Veterans Affairs Epilepsy Cooperative study No 264 group. (1992). A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med, 37 : 765-771.
67. MATTSON R.H., PETROFF O., et al. (1994). Vigabatrin : effects on human brain GABA levels by nuclear magnetic resonance spectroscopy. Epilepsia, 35 (Suppl. 5) : S29-S32.
68. MESSENHEIMER J.A., RAMSAY R.E., WILLMORE L.J., LEROY R.F., ZIELENSKI J.J., MATTSON R., PELLOCK J.M., VALAKAS A.M., WOMBLE G., RISNER M. (1994). Lamotrigine therapy for partial seizures ; a multicenter, placebo-controlled, cross-over trial. Epilepsia, 35 : 113-121.
69. MESSENHEIMER J.A. (1995). Lamotrigine. Epilepsia, 36 (Suppl. 2) : S87-S94.
70. MICHELUTTI R., TASSINARI C.A. (1989). Response to vigabatrin in relation to seizure type. Br J Clin Pharmacol, 27 : 119-124.
71. MUMFORD J.P., DAM M. (1989). Meta-analysis of placebo-controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol, 27 : 101S-107S.
72. OLLER L.F.V., RUSSI A., DAURELLA L.O. (1991). Lamotrigine in the Lennox-Gastaut syndrome. Epilepsia, 32 (Suppl. 1) : 58.
73. PISANI F., GALLITTO G., Di PERRI R. (1991). Could lamotrigine be useful in status epilepticus ? A case report. J Neurol Neurosurg Psychiatry, 54 : 845-846.
74. PORTER R.J., ROGAWSKI M.A. (1992). New antiepileptic drugs : from serendipity to rational discovery. Epilepsia, 33 (Suppl. 1 ) : S1-S6.
75. REMY C., BEAUMONT D. (1989). Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. Br J Clin Pharmacol, 27 (Suppl. 1) : 125S-129S.
76. RICHENS A., CHADWICK D.W., DUNCAN J.S. (1995). Adjunctive treatment of partial seizures with tiagabine. Epilepsy Res, 21 : 37-42.
77. RIMMER E.M., RICHENS A. (1984). Double-blind study of gammavinyl GABA in patients with refractory epilepsy. Lancet, ii : 189-190.
78. RING H.A., CRELLIN R., KIRKER S., REYNOLDS E.H. (1993). Vigabatrin and depression. J Neurol Neurosurg Psychiatry, 56 : 925-928.
79. ROGER J., BUREAU M., DRAVET CH., DREIFUSS F.E., PERRET A., WOLF P. (1992). Les syndromes épileptiques de l'enfant et de l'adolescent. John Libbey Ed.
80. SANDER J.W.A.S, HART Y.M., TRIMBLE M.R., SHORVON S.D. (1991). Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry, 54 : 435-439.
81. SCHLUMBERGER E., CHAVEZ R, PALACIOS L., REY E., PAJOT N., DULAC O. (1994). Lamotrigine in treatment of 120 children with epilepsy. Epilepsia, 35 : 359-367.
82. SILFENIUS H. (1988). Economic costs of epilepsy-treatment benefits. Acta Neural Scand, 78 (Suppl. 117) : 136-154.
83. SMITH D., CHADWICK D.W., BAKER G., DAVIS G., DEWEY M. (1993). Seizure severity and the quality of life. Epilepsia, 34 (Suppl. 5) : S31-S35.
84. STRUMIA S., HIRSCH E., MOSZKOWSKI J., MARESCAUX C. (1994). Lamotrigine effect in typical absences. Epilepsia, 35 (Suppl. 8) : 118.
85. TANGANELLI P., REGESTRA P. (1994). Vigabatrin versus carbamazepine monotherapy in newly diagnosed epileptics. A randomized response conditional cross-over study. Epilepsia, 35 (Suppl. 7) : S64.
86. TASSINARI C.A., MICHELUCCI R., AMBROSETO G. et al. (1987). Double-blind study of vigabatrin in the treatment of drug resistant epilepsy. Arch Neurol, 44 : 907-910.
87. TAYLOR C.P. (1995). Gabapentin, mechanisms of action. In : Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs, Fourth Edition. New York : Raven Press, pp. 829-841.
88. THE UK GABAPENTIN STUDY GROUP. (1990). Gabapentin in partial epilepsy. Lancet, 335 : 1114-1117.
89. THE US GABAPENTIN STUDY GROUP No 5. (1995). Gabapentin as add-on therapy in refractory partial epilepsy : a double-blind, placebo-controlled, parallel-group study. Neurology, 43 : 2292-2298.
90. THE US GABAPENTIN STUDY GROUP. (1994). The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Res, 18 : 67-73.
91. TIMMINGS P.L., RICHENS A. (1992). Lamotrigine as add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol, 32 : 305-307.
92. UPTON N. (1994). Mechanisms of action of new antiepileptic drugs : rational design and serendipitous findings. Trends in Pharmacological Sciences, 15 : 456-463.
93. VERGNES M., MARESCAUX C. (1994). Pathophysiological mechanisms underlying genetic absence epilepsy in rats. In : Mafosse A., Genton P., Hirsch E., Broglin D., Bemasconi R.. Idiopathic generalized epilepsies : clinical, experimental and genetic aspects. London : J Libbey, pp. 151-168.
94. WALLACE S.J. (1989). Lamotrigine in resistant childhood epilepsy. Neuropediatric, 20 : 116.
95. WOLF P. (1992). Lamotrigine : preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. J Epilepsy, 5 : 73-79.
96. YUEN A.W.C. LAND G., WEATHERLEY B.C., PECK A.W. (1992). Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol, 33 : 511-513.